Objectives: To determine how many patients may have received a mistaken diagnosis of coeliac disease using the ESPGHAN 2012 and 2020 criteria without performance of biopsy when using chemiluminescence, and to evaluate possible causes of interference affecting anti-tissue transglutaminase antibody results obtained with this technique.
Methods: Retrospective and descriptive study of biopsies of patients with elevated tissue transglutaminase antibodies (tTGA) measured by chemiluminescence in a tertiary care hospital.
Results: The sample included 135 patients with a mean age of 7.7 years. The diagnosis of coeliac disease was confirmed in 67 (49.6%) and ruled out in the remaining 68 (50.4%). Subsequently, among those with a non-diagnostic biopsy, we found that 13 (19.1%) would have met the ESPGHAN 2012 criteria and 17 (25%) the ESPGHAN 2020 criteria. The tTG antibody levels were greater than 10 times the upper limit of normal (ULN) in 27.9%. In patients who tested positive for endomysial antibodies (EMA), the cut-off point for tTGA measured by chemiluminescence that achieved the best combined sensitivity and specificity (Youden index) was 849U/mL (42.5×ULN). On the other hand, if EMA levels were not taken into account, the cut-off point was 301U/mL (15×ULN). In addition, 16 patients (23.5%) received a diagnosis of chronic gastritis secondary to Helicobacter pylori (HP) infection, of who 50% fulfilled the ESPGHAN 2012 and 2020 criteria for diagnosis without biopsy.
Conclusions: Transglutaminase antibody levels measured by chemiluminescence offer a high sensitivity, but there can be artifacts due to situations such as infection by HP. Therefore, the ESPGHAN guidelines must be revised for application in this particular case.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.anpede.2025.503742 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Are the ESPGHAN criteria valid with the chemioluminiscence method? Analysis of potential diagnostic errors.
An Pediatr (Engl Ed)
March 2025
Servicio de Bioquímica, Hospital Universitario Miguel Servet, Zaragoza, Spain.
Objectives: To determine how many patients may have received a mistaken diagnosis of coeliac disease using the ESPGHAN 2012 and 2020 criteria without performance of biopsy when using chemiluminescence, and to evaluate possible causes of interference affecting anti-tissue transglutaminase antibody results obtained with this technique.
Methods: Retrospective and descriptive study of biopsies of patients with elevated tissue transglutaminase antibodies (tTGA) measured by chemiluminescence in a tertiary care hospital.
Results: The sample included 135 patients with a mean age of 7.
Coeliac Disease in Children-A Clinical Review Including Novel Treatment Agents.
Medicina (Kaunas)
October 2024
Department of Gastroenterology, Perth Children's Hospital, Perth, WA 6009, Australia.
Coeliac disease (CD) affects almost of 1% of the population, yet remains undiagnosed in the majority. Though the demonstration of enteropathy in duodenal biopsy was traditionally the essential criterion for the diagnosis of coeliac disease, the guidelines published by the European Society of Paediatric Gastroenterology and Nutrition (ESPGHAN) in 2012, and revised in 2020, paved the way to a no-biopsy approach to diagnosis. In a select group of children meeting certain criteria, a definitive diagnosis of CD can now be made without the need for duodenal biopsies.
View Article and Find Full Text PDFWith or without biopsy in coeliac children?-Impact on dietary compliance and quality of life.
Eur J Pediatr
October 2024
Department of Paediatrics, Rijnstate Hospital, Wagnerlaan 55, 6815 AD, Arnhem, the Netherlands.
Article Synopsis
- Critics of the ESPGHAN guidelines on celiac disease (CD) raise concerns about the no-biopsy policy and its acceptance among patients and families, as it leads to a lifelong diagnosis.
- This study evaluated the effects of this no-biopsy approach on dietary adherence and health-related quality of life (HRQOL) among diagnosed patients.
- Results indicated that while dietary compliance was consistent across different diagnostic groups, patients diagnosed via biopsies scored better in certain HRQOL measures compared to those diagnosed without biopsies, suggesting that the no-biopsy method did not negatively impact overall dietary adherence or quality of life.
Clinical guideline highlights for the hospitalist: Evaluation, management, and prevention of cow's milk allergy.
J Hosp Med
May 2024
Department of Pediatrics, Division of Pediatric Hospital Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
An ESPGHAN position paper on the diagnosis, management and prevention of cow's milk allergy RELEASE DATE: Journal of Pediatric Gastroenterology and Nutrition, July 26, 2023 PRIOR VERSION: 2012 DEVELOPER: ESPGHAN (European Society of Paediatric Gastroenterology, Hepatology and Nutrition), NASPGHAN (North American Society of Pediatric Gastroenterology, Hepatology and Nutrition) FUNDING SOURCE: ESPGHAN TARGET POPULATION: Infants and young children with suspected cow's milk allergy.
View Article and Find Full Text PDFNew and old criteria for diagnosing celiac disease: do they really differ? A retrospective observational study.
Ital J Pediatr
April 2024
Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), School of Medicine, University of Palermo, Palermo, Italy.
Background: The aim of this study is to compare two groups of celiac patients: the first one, in which diagnosis was based on a "biopsy sparing" approach according to the 2012 ESPGHAN criteria, and the second one, based on the biopsy approach like the one of the 1991 Revised Criteria, in order to find relevant difference for sex, M/F ratio, age at diagnosis, clinical features at the onset, presence and prevalence of concomitant autoimmune disorders.
Methods: Our study involves 61 patients having the Celiac Disease (CD) onset from February 2013 to February 2020. The 32 patients who received diagnosis according "biopsy sparing" criteria were enrolled in group (1) The 29 patients who received diagnosis by duodenal biopsy were enrolled in group (2) Prevalence of comorbidities was analysed through chi-square test.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!